A Survey of Saudi General Practitioners on the Use of Thromboprophylaxis Guidelines and Risk Assessment Tools in Atrial Fibrillation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Inclusion and Exclusion Criteria
2.3. Data Collection
2.4. Ethical Considerations
2.5. Sample Size and Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Variable | Frequency (%) |
---|---|
Strengths of clinical guidelines | |
Clear recommendations | 56 (27.9%) |
Detailed recommendations supported by evidence | 34 (16.9%) |
Easy to follow algorithms | 39 (19.4%) |
Online availability | 27 (13.4%) |
Clinical applicability/flexibility | 22 (10.9%) |
Concise | 22 (10.9%) |
Most authoritative guideline in Australia | 0 |
Major limitations of clinical guidelines | |
I have not noticed any major limitations. | 68 (33.8%) |
Too long | 38 (18.9%) |
Difficult to access/not user-friendly | 31 (15.4%) |
Do not consider patient preferences | 16 (8.0%) |
Limited clinical flexibility (not patient-specific) | 28 (13.9%) |
Unclear recommendations | 4 (2.0%) |
Difficult to follow algorithms | 15 (7.5%) |
Helpfulness of clinical guidelines in challenging/ uncertain clinical decisions | |
Very helpful | 70 (34.8%) |
Helpful | 98 (48.8%) |
Slightly helpful | 29 (14.4%) |
Not helpful at all | 3 (1.5%) |
References
- Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.-C.; Heidbuchel, H.; Hendriks, J.; et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardio-Thoracic Surg. 2016, 50, e1–e88. [Google Scholar] [CrossRef] [PubMed]
- Dai, H.; Zhang, Q.; Abu Much, A.; Maor, E.; Segev, A.; Beinart, R.; Adawi, S.; Lu, Y.; Bragazzi, N.L.; Wu, J. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: Results from the Global Burden of Disease Study 2017. Eur. Heart J. Qual. Care Clin. Outcomes 2020, 7, 574–582. [Google Scholar] [CrossRef] [PubMed]
- Brieger, D.; Amerena, J.; Attia, J.; Bajorek, B.; Chan, K.H.; Connell, C.; Freedman, B.; Ferguson, C.; Hall, T.; Haqqani, H.; et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018, 27, 1209–1266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.-A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021, 42, 373–498. [Google Scholar] [CrossRef] [PubMed]
- January, C.T.; Wann, L.S.; Calkins, H.; Chen, L.Y.; Cigarroa, J.E.; Cleveland, J.C., Jr.; Ellinor, P.T., Jr.; Ezekowitz, M.D.; Field, M.E.; Furie, K.L.; et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019, 140, e125–e151. [Google Scholar] [CrossRef]
- Albertsen, I.E.; Rasmussen, L.H.; Overvad, T.F.; Graungaard, T.; Larsen, T.B.; Lip, G.Y. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A systematic review and meta-analysis. Stroke 2013, 44, 1329–1336. [Google Scholar] [CrossRef] [Green Version]
- Lip, G.Y.; Laroche, C.; Popescu, M.I.; Rasmussen, L.H.; Vitali-Serdoz, L.; Dan, G.-A.; Kalarus, Z.; Crijns, H.J.; Oliveira, M.; Tavazzi, L.; et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: A report from the EORP-AF General Pilot Registry. EP Eur. 2015, 17, 1777–1786. [Google Scholar] [CrossRef]
- Gebreyohannes, E.A.; Salter, S.; Chalmers, L.; Bereznicki, L.; Lee, K. Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence. Am. J. Cardiovasc. Drugs 2021, 21, 419–433. [Google Scholar] [CrossRef]
- Admassie, E.; Chalmers, L.; Bereznicki, L.R. Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients with Atrial Fibrillation. Am. J. Cardiol. 2017, 120, 1133–1138. [Google Scholar] [CrossRef]
- Rathinam, I.; Anoopkumar-Dukie, S.; Badrick, T.; Teasdale, T.; Bernaitis, N. Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia. Heart Lung Circ. 2020, 29, e222–e230. [Google Scholar] [CrossRef]
- Bezabhe, W.M.; Bereznicki, L.R.; Radford, J.; Wimmer, B.C.; Curtain, C.; Salahudeen, M.S.; Peterson, G.M. Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients with Atrial Fibrillation. Front. Pharmacol. 2021, 12, 586370. [Google Scholar] [CrossRef]
- Bezabhe, W.M.; Bereznicki, L.R.; Radford, J.; Wimmer, B.C.; Salahudeen, M.S.; Garrahy, E.; Bindoff, I.; Peterson, G.M. Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. Eur. J. Clin. Investig. 2021, 51, e13489. [Google Scholar] [CrossRef] [PubMed]
- Berti, D.; Moors, E.; Moons, P.; Heidbuchel, H. Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients. Heart 2015, 101, 884–893. [Google Scholar] [CrossRef] [PubMed]
- Bista, D.; Chalmers, L.; Peterson, G.M.; Bereznicki, L.R.E. Patient Characteristics and Antithrombotic Prescribing Patterns in Patients with Atrial Fibrillation in Tasmania. Clin. Appl. Thromb./Hemost 2017, 23, 438–444. [Google Scholar] [CrossRef] [PubMed]
- Frain, B.; Castelino, R.; Bereznicki, L.R. The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities with Atrial Fibrillation. Clin. Appl. Thromb./Hemost 2018, 24, 519–524. [Google Scholar] [CrossRef]
- Gebreyohannes, E.A.; Salter, S.M.; Chalmers, L.; Bereznicki, L.; Lee, K. Reasons for non-adherence to thromboprophylaxis prescribing guidelines in atrial fibrillation in Western Australia: A qualitative descriptive study of general practitioners' views. Thromb. Res. 2021, 208, 83–91. [Google Scholar] [CrossRef]
- Kirley, K.; Rao, G.; Bauer, V.; Masi, C. The Role of NOACs in Atrial Fibrillation Management: A Qualitative Study. J. Atr. Fibrillation 2016, 9, 1416. [Google Scholar] [CrossRef]
- Pokorney, S.D.; Bloom, D.; Granger, C.B.; Thomas, K.L.; Al-Khatib, S.M.; Roettig, M.L.; Anderson, J., Jr.; Heflin, M.T.; Granger, B.B. Exploring patient–provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. Eur. J. Cardiovasc. Nurs. 2018, 18, 280–288. [Google Scholar] [CrossRef]
- Heidbuchel, H.; Dagres, N.; Antz, M.; Kuck, K.-H.; Lazure, P.; Murray, S.; Carrera, C.; Hindricks, G.; Vahanian, A. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: A European Society of Cardiology international educational needs assessment. EP Eur. 2018, 20, 1919–1928. [Google Scholar] [CrossRef]
- Cimminiello, C.; Hatala, R.; Pakarinen, S.; Friz, H.P.; Fitzmaurice, D.; Hobbs, F.R. Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open 2018, 2, bjgpopen18X101602. [Google Scholar] [CrossRef]
- Ministry of Health. Atrial Fibrillation: Clinical Practice Guideline on Antithrombotic Treatment of Patients with Non-valvular Atrial Fibrillation. 2014. Available online: https://www.moh.gov.sa/en/Ministry/Structure/Programs/TCP/Documents/2.%20Atrial%20Fibrillation%20-%20Antithrombotic%20Treatment%20of%20Patients%20with%20Non-valvular%20Atrial%20Fibrillation.pdf. (accessed on 14 December 2022).
- Almatrudi, T.A.; Rabbani, U. Awareness, attitude, and practice of evidence-based medicine among primary healthcare physicians in Buraidah, Saudi Arabia. J. Fam. Med. Prim. Care 2022, 11, 5457–5463. [Google Scholar] [CrossRef]
- Gebreyohannes, E.A.; Salter, S.M.; Chalmers, L.; Radford, J.; Lee, K. Use of thromboprophylaxis guidelines and risk stratification tools in atrial fibrillation: A survey of general practitioners in Australia. J. Eval. Clin. Pract. 2022, 28, 483–492. [Google Scholar] [CrossRef]
- Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandenbroucke, J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [Google Scholar] [CrossRef] [Green Version]
- Raosoft Inc. 2004. Available online: http://www.raosoft.com/samplesize.html (accessed on 2 May 2022).
- AlShoaibi, N.; Al Harbi, M.; Modaimegh, H.; Al Qubbany, A.; Al Saif, S.; Connolly, D.; Kharabsheh, S.; Fathy, M.; Hegazy, Y.; Tarcha, N.; et al. Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. Expert Rev. Cardiovasc. Ther. 2021, 19, 221–236. [Google Scholar] [CrossRef]
- Jatau, A.I.; Bereznicki, L.R.; Wimmer, B.C.; Bezabhe, W.M.; Peterson, G.M. Improving Knowledge and Early Detection of Atrial Fibrillation through a Community-Based Opportunistic Screening Program: What’s Your Beat? Int. J. Environ. Res. Public Health 2022, 19, 6860. [Google Scholar] [CrossRef]
- Krittayaphong, R.; Winijkul, A.; Kunjara-Na-Ayudhya, R.; Apiyasawat, S.; Siriwattana, K.; Kanjanarutjawiwat, W.; Dutsadeevettakul, S.; Lip, G.Y.H. for the COOL-AF Investigators Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population. Stroke 2020, 51, 1772–1780. [Google Scholar] [CrossRef] [PubMed]
- Olivia, C.; Hastie, C.; Farshid, A. Adherence to guidelines regarding anticoagulation and risk factors for progression of atrial fibrillation in a nurse-led clinic. Intern. Med. J. 2020, 51, 1136–1142. [Google Scholar] [CrossRef] [PubMed]
- Joung, B.; Lee, J.M.; Lee, K.H.; Kim, T.-H.; Choi, E.-K.; Lim, W.-H.; Kang, K.-W.; Shim, J.; Lim, H.E.; Park, J.; et al. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ. J. 2018, 48, 1033–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van der Endt, V.H.W.; Milders, J.; de Vries, B.B.L.P.; A Trines, S.; Groenwold, R.H.H.; Dekkers, O.M.; Trevisan, M.; Carrero, J.J.; van Diepen, M.; Dekker, F.W.; et al. Comprehensive comparison of stroke risk score performance: A systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. Europace 2022, 24, 1739–1753. [Google Scholar] [CrossRef] [PubMed]
- Al-Hameed, F.M.; Al-Dorzi, H.M.; Al-Momen, A.M.; Algahtani, F.H.; Al-Zahrani, H.A.; Al-Saleh, K.A.; Al-Sheef, M.A.; Owaidah, T.M.; Alhazzani, W.; Neumann, I.; et al. The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism: Outpatient versus inpatient management. Saudi Med. J. 2015, 36, 1004–1010. [Google Scholar] [CrossRef] [PubMed]
Variable | Frequency (%) |
---|---|
Age Category | |
<30 years | 67 (33.3) |
30–39 years | 64 (31.8) |
40–49 years | 46 (22.9) |
50–59 years | 20 (10.0) |
60–70 years | 3 (1.5) |
>70 years | 0 (0.0) |
Gender | |
Male | 120 (59.7) |
Female | 80 (39.8) |
Educational level | |
Bachelor’s degree | 117 (58.2) |
Master’s degree | 57 (28.4) |
PhD degree | 26 (12.9) |
Variable | Frequency (%) |
---|---|
Source of information to guide thromboprophylaxis decisions in AF | |
Directly through clinical guidelines | 112(55.7) |
Educational sessions (e.g., webinars) | 30(14.9) |
Online CME/CPD websites (e.g., Center for Consulting and Health Skills Training) | 35(17.4) |
Reading of the scientific literature | 23(11.4) |
Frequency of using a guideline | |
When managing patients newly diagnosed with AF | 56(27.9%) |
When a clinical decision about anticoagulation is challenging or uncertain | 57(28.4%) |
When a new version of the guideline is available | 44(21.9%) |
Every time I manage a patient with AF | 43(21.4%) |
Reasons for not using AF clinical guidelines as a primary resource | |
Too many guidelines to choose from | 50(24.9) |
Too many guidelines for different disease conditions | 70(34.8) |
The guidelines are very long and time-consuming | 33(16.4) |
The guidelines sometimes disagree with each other | 24(11.9) |
The guidelines sometimes disagree with PBS criteria | 8(4.0) |
My busy schedule | 4(2.0) |
Preference/better familiarity with other options (e.g., GARFIELD tool) | 11(5.5) |
Variables | Frequency (%) |
---|---|
Preferred formal stroke risk assessment tool | |
CHA2DS2-VASc | 106(52.7%) |
CHA2DS2-VA | 45(22.4%) |
CHADS2 | 35(17.4%) |
GARFIELD | 14(7.0%) |
Frequency of using the preferred formal bleeding risk assessment tool | |
As part of a regular review (e.g., every 6–12 months) | 33 (16.4%) |
Whenever a patient’s comorbidities change | 57 (28.4%) |
When newly initiating patients on oral anticoagulation therapy | 69 (34.3%) |
Every time a patient has a new medication prescribed | 24 (11.9%) |
Every time the patient visits my office | 7 (3.5%) |
Others | 10 (5.0%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alnami, M.I.; Alsalim, A.M.; Alhakeem, R.F.; Al-Somali, B.A.; Bahkali, H.A.; Alhabshi, H.A.; Alotaibi, H.T.; Alqallaf, R.A.; Ali, S. A Survey of Saudi General Practitioners on the Use of Thromboprophylaxis Guidelines and Risk Assessment Tools in Atrial Fibrillation. Clin. Pract. 2023, 13, 347-356. https://doi.org/10.3390/clinpract13020031
Alnami MI, Alsalim AM, Alhakeem RF, Al-Somali BA, Bahkali HA, Alhabshi HA, Alotaibi HT, Alqallaf RA, Ali S. A Survey of Saudi General Practitioners on the Use of Thromboprophylaxis Guidelines and Risk Assessment Tools in Atrial Fibrillation. Clinics and Practice. 2023; 13(2):347-356. https://doi.org/10.3390/clinpract13020031
Chicago/Turabian StyleAlnami, Mohammed Ibrahim, Ali Mansoor Alsalim, Ruwaida Faisal Alhakeem, Bushra Abdulrahman Al-Somali, Haitham Ali Bahkali, Hanaa Ali Alhabshi, Hailah Talaq Alotaibi, Rahma Abdulrazzaq Alqallaf, and Sheraz Ali. 2023. "A Survey of Saudi General Practitioners on the Use of Thromboprophylaxis Guidelines and Risk Assessment Tools in Atrial Fibrillation" Clinics and Practice 13, no. 2: 347-356. https://doi.org/10.3390/clinpract13020031
APA StyleAlnami, M. I., Alsalim, A. M., Alhakeem, R. F., Al-Somali, B. A., Bahkali, H. A., Alhabshi, H. A., Alotaibi, H. T., Alqallaf, R. A., & Ali, S. (2023). A Survey of Saudi General Practitioners on the Use of Thromboprophylaxis Guidelines and Risk Assessment Tools in Atrial Fibrillation. Clinics and Practice, 13(2), 347-356. https://doi.org/10.3390/clinpract13020031